These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

736 related articles for article (PubMed ID: 33761582)

  • 1. Super-rapid race for saving lives by developing COVID-19 vaccines.
    Uttarilli A; Amalakanti S; Kommoju PR; Sharma S; Goyal P; Manjunath GK; Upadhayay V; Parveen A; Tandon R; Prasad KS; Dakal TC; Ben Shlomo I; Yousef M; Neerathilingam M; Kumar A
    J Integr Bioinform; 2021 Mar; 18(1):27-43. PubMed ID: 33761582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.
    Lambert PH; Ambrosino DM; Andersen SR; Baric RS; Black SB; Chen RT; Dekker CL; Didierlaurent AM; Graham BS; Martin SD; Molrine DC; Perlman S; Picard-Fraser PA; Pollard AJ; Qin C; Subbarao K; Cramer JP
    Vaccine; 2020 Jun; 38(31):4783-4791. PubMed ID: 32507409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coronavirus Vaccine: Light at the End of the Tunnel.
    Ella KM; Mohan VK
    Indian Pediatr; 2020 May; 57(5):407-410. PubMed ID: 32291382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates.
    Ura T; Yamashita A; Mizuki N; Okuda K; Shimada M
    Vaccine; 2021 Jan; 39(2):197-201. PubMed ID: 33279318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [SARS-CoV-2 vaccines].
    Benfield TL; Helweg-Larsen J
    Ugeskr Laeger; 2021 Mar; 183(10):. PubMed ID: 33734065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deciphering Vaccines for COVID-19: where do we stand today?
    Baviskar T; Raut D; Bhatt LK
    Immunopharmacol Immunotoxicol; 2021 Feb; 43(1):8-21. PubMed ID: 33054486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of Traditional Vaccine Development Strategies to SARS-CoV-2.
    Rando HM; Lordan R; Lee AJ; Naik A; Wellhausen N; Sell E; Kolla L; ; Gitter A; Greene CS
    mSystems; 2023 Apr; 8(2):e0092722. PubMed ID: 36861991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frontrunners in the race to develop a SARS-CoV-2 vaccine.
    Russell RL; Pelka P; Mark BL
    Can J Microbiol; 2021 Mar; 67(3):189-212. PubMed ID: 33264067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. mRNA vaccines for COVID-19: what, why and how.
    Park JW; Lagniton PNP; Liu Y; Xu RH
    Int J Biol Sci; 2021; 17(6):1446-1460. PubMed ID: 33907508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Latest in COVID-19 Vaccine 'Candidates' Race.
    Atoum MF; Zreig DA; Abu Zreig LM
    Infect Disord Drug Targets; 2023; 23(1):e180822207640. PubMed ID: 35984031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A COVID-19 vaccine-dare to dream.
    Phillis A
    Br J Community Nurs; 2020 Dec; 25(12):2-7. PubMed ID: 33275510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An evidence-based systematic review on emerging therapeutic and preventive strategies to treat novel coronavirus (SARS-CoV-2) during an outbreak scenario.
    Gudadappanavar AM; Benni J
    J Basic Clin Physiol Pharmacol; 2020 Sep; 31(6):. PubMed ID: 32924964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current advances and challenges in COVID-19 vaccine development: from conventional vaccines to next-generation vaccine platforms.
    Jafari A; Danesh Pouya F; Niknam Z; Abdollahpour-Alitappeh M; Rezaei-Tavirani M; Rasmi Y
    Mol Biol Rep; 2022 Jun; 49(6):4943-4957. PubMed ID: 35235159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efforts towards a COVID-19 vaccine.
    Brüssow H
    Environ Microbiol; 2020 Oct; 22(10):4071-4084. PubMed ID: 32893468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The race for a COVID-19 vaccine: where are we up to?
    Hossain MK; Hassanzadeganroudsari M; Feehan J; Apostolopoulos V
    Expert Rev Vaccines; 2022 Mar; 21(3):355-376. PubMed ID: 34937492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lessons From Bacille Calmette-Guérin for SARS-CoV-2 Vaccine Candidates.
    Behr MA; Divangahi M; Schurr E
    J Infect Dis; 2021 Feb; 223(2):189-191. PubMed ID: 33535239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need.
    Jin P; Li J; Pan H; Wu Y; Zhu F
    Signal Transduct Target Ther; 2021 Feb; 6(1):48. PubMed ID: 33531462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of vaccines for SARS-CoV-2.
    Ng WH; Liu X; Mahalingam S
    F1000Res; 2020; 9():. PubMed ID: 32850116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COVID-19 - Important considerations for developing and using a vaccine.
    Rahman IU; Ali N; Ijaz F; Afzal A; Abd Allah EF
    Hum Vaccin Immunother; 2021 Feb; 17(2):414-415. PubMed ID: 32693665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.